Real-world data confirm the effectiveness of caplacizum thrombocytopenic purpura

Blood Advances

4, 3085-3092

DOI: 10.1182/bloodadvances.2020001973

Citation Report

#	Article	IF	Citations
1	Caplacizumab: frequent local skin reactions. Annals of Hematology, 2021, 100, 3051-3052.	0.8	3
2	Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab. Journal of Thrombosis and Haemostasis, 2020, 18, 3061-3066.	1.9	37
3	A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura. Expert Review of Hematology, 2020, 13, 1153-1164.	1.0	8
4	Caplacizumab. Reactions Weekly, 2020, 1820, 82-82.	0.0	0
5	ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP. Blood Advances, 2020, 4, 3093-3101.	2.5	43
6	A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood, 2021, 137, 733-742.	0.6	95
7	Successful use of caplacizumab in a case of refractory acquired thrombotic thrombocytopenic purpura following subacute thyroiditis. Transfusion and Apheresis Science, 2021, 60, 103010.	0.5	0
8	Should all patients with immuneâ€mediated thrombotic thrombocytopenic purpura receive caplacizumab?. Journal of Thrombosis and Haemostasis, 2021, 19, 58-67.	1.9	19
9	Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI). Transfusion and Apheresis Science, 2021, 60, 103011.	0.5	12
11	Thrombotic Thrombocytopenic Purpura: When Basic Science Meets Clinical Research. Hamostaseologie, 2021, 41, 283-293.	0.9	1
12	TTP: the evolution of clinical practice. Blood, 2021, 137, 719-720.	0.6	11
13	Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children. Pediatric Blood and Cancer, 2021, 68, e28949.	0.8	13
14	Incidence, diagnosis, and outcome of immuneâ€mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis, 2021, 36, 563-573.	0.7	11
15	Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Advances, 2021, 5, 2137-2141.	2.5	39
16	Redefining outcomes in immune TTP: an international working group consensus report. Blood, 2021, 137, 1855-1861.	0.6	103
17	Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab. Journal of Thrombosis and Haemostasis, 2021, 19, 1922-1925.	1.9	10
18	The standard of care for immune thrombotic thrombocytopenic purpura today. Journal of Thrombosis and Haemostasis, 2021, 19, 1864-1871.	1.9	12
19	Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions. Therapeutics and Clinical Risk Management, 2021, Volume 17, 577-587.	0.9	6

#	Article	IF	Citations
20	Treating thrombotic thrombocytopenic purpura without plasma exchange during the COVID-19 pandemic. A case report and a brief literature review. Transfusion and Apheresis Science, 2021, 60, 103107.	0.5	1
21	Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution. Journal of Clinical Medicine, 2021, 10, 3418.	1.0	2
22	Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?. Expert Review of Clinical Pharmacology, 2021, 14, 1183-1188.	1.3	9
24	Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura. Expert Review of Hematology, 2021, 14, 707-719.	1.0	7
26	Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist. American Journal of Hematology, 2021, 96, 1655-1665.	2.0	16
27	Successful use of a second course of caplacizumab in relapsed thrombotic thrombocytopenic purpura. Platelets, 2022, 33, 790-791.	1.1	1
28	First use of the antiâ€VWF nanobody caplacizumab to treat iTTP in pregnancy. British Journal of Haematology, 2022, 196, .	1.2	17
29	Burden of illness among Medicare and non-Medicare US populations with acquired thrombotic thrombocytopenic purpura. Journal of Medical Economics, 2021, 24, 706-716.	1.0	5
30	Cost analysis of the impact of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura from a US hospital perspective. Journal of Medical Economics, 2021, 24, 1178-1184.	1.0	3
31	Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era. Annals of Hematology, 2022, 101, 59-67.	0.8	9
32	Case Report: Two Cases of Pediatric Thrombotic Thrombocytopenic Purpura Treated With Combined Therapy. Frontiers in Pediatrics, 2021, 9, 743206.	0.9	7
33	Alternateâ€day dosing of caplacizumab for immuneâ€mediated thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2022, 20, 951-960.	1.9	15
34	<scp>TTP</scp>: From empiricism for an enigmatic disease to targeted molecular therapies. British Journal of Haematology, 2022, 197, 156-170.	1.2	12
35	Advances in the management of TTP. Blood Reviews, 2022, 55, 100945.	2.8	15
36	European Renal Best Practice endorsement of guidelines for diagnosis and therapy of thrombotic thrombocytopaenic purpura published by the International Society on Thrombosis and Haemostasis. Nephrology Dialysis Transplantation, 2022, 37, 1229-1234.	0.4	5
37	Mind and matter: The neurological complications of thrombotic thrombocytopenic purpura. British Journal of Haematology, 2022, 197, 529-538.	1.2	8
38	Focus on Key Issues in Immune Thrombotic Thrombocytopenic Purpura: Italian Experience of Six Centers. Journal of Clinical Medicine, 2021, 10, 5702.	1.0	0
39	Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTSâ€13 activity and autoantibodies. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12606.	1.0	1

#	Article	IF	Citations
40	Nanobodies dismantle postâ€pyroptotic ASC specks and counteract inflammation inÂvivo. EMBO Molecular Medicine, 2022, 14, e15415.	3.3	18
41	Unmet needs in the management of immuneâ€mediated thrombotic thrombocytopenic purpura and the potential role of caplacizumab in the UKâ€"A modifiedâ€Delphi study. EJHaem, 2022, 3, 619-627.	0.4	1
42	Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura. Medicina ClÃnica (English Edition), 2022, 158, 630.e1-630.e14.	0.1	1
43	Thrombotic Thrombocytopenic Purpura: From 1972 to 2022 and Beyond. Seminars in Thrombosis and Hemostasis, 2022, 48, 926-936.	1.5	3
44	Real-world effectiveness of caplacizumab vs the standard of care inÂimmune thrombotic thrombocytopenic purpura. Blood Advances, 2022, 6, 6219-6227.	2.5	20
45	Caplacizumab in the successful management of cardiac involvement in thrombotic thrombocytopenic purpura. Baylor University Medical Center Proceedings, 0, , 1-2.	0.2	0
46	Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immuneâ€mediated thrombotic thrombocytopenic purpura in the United States. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12802.	1.0	7
47	Clinical features and neurological outcomes in pediatric immuneâ€mediated thrombotic thrombocytopenic purpura: A report from a large pediatric hematology center. Pediatric Blood and Cancer, 0, , .	0.8	2
48	Realâ€world data with the use of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura: A singleâ€center with homogeneous treatment experience. Transfusion, 2022, 62, 2363-2369.	0.8	8
49	Longâ€term followâ€up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Postâ€HERCULES study. Journal of Thrombosis and Haemostasis, 2022, 20, 2810-2822.	1.9	11
50	Thrombotic thrombocytopenic purpura after vaccination for COVID-19: lesson for the clinical nephrologist. Journal of Nephrology, 0, , .	0.9	1
52	Health following recovery from immune thrombotic thrombocytopenic purpura: the patientâ€™s perspective. Blood Advances, 2023, 7, 1813-1822.	2.5	3
53	More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura. Blood Advances, 0, , .	2.5	1
54	Recurrent Thrombotic Microangiopathy in a Kidney Transplant Recipient. , 2022, , 255-264.		1
55	Caplacizumab as frontline therapy in addition to standard treatment in iTTP. Blood Advances, 0, , .	2.5	0
56	Evidence-Based Minireview: Should caplacizumab be used routinely in unselected patients with immune thrombotic thrombocytopenic purpura?. Hematology American Society of Hematology Education Program, 2022, 2022, 491-494.	0.9	5
59	Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience. Platelets, 2023, 34, .	1.1	5
60	Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2023, 21, 559-572.	1.9	10

#	Article	IF	Citations
61	Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura. International Journal of Hematology, 2023, 117, 331-340.	0.7	3
62	Linking Patient Experience to Customer Delight in the Private Laboratory Service. Administrative Sciences, 2023, 13, 71.	1.5	0